Germany Pharmaceuticals Market Share,
Revenue, Drivers, Trends And Influence Factors
Historical & Forecast Till 2025
The Germany Pharmaceuticals Market size is projected to touch USD 65.9 billion by 2027, according to a new
report by Million Insights. The market is anticipated to register 6.0% CAGR over the forecast duration. Growing
prevalence of chronic diseases and rise on the expenditure on research and development are attributing to
the growth of the market.
In addition, an increasing number of clinical trials for novel immune-suppressive therapies is projected to bode
well for the growth of the market. For example, Sandoz International GmbH introduced Dailiport capsules in
June 2020 in European countries including Germany.
Major market participants are increasingly focusing on strategic initiatives such as merger & acquisition,
partnerships and collaboration to consolidate their market presence. For example, Bristol-Myers Squibb made
an acquisition of Celgene Corporation in 2019 to expand its product portfolio in oncology.
Browse Full Research Report @
The rising availability of cost-effective generic drugs is projected to fuel market growth over the next few
years. German companies are focusing on introducing the generic drug to consolidate their market presence.
For example, Sandoz of Novartis AG, in mid-2019, introduced gefitinib’s generic version.
Germany Pharmaceuticals Market Report provides in-depth analysis of industry by
production, share, size, Demand, Proposition, Development, Opportunities, Growth,
Economic Trends, Technologies Research, Segmentation, Key Futuristic, Investment
Feasibility, Major Key Players, SWOT analysis and Forecast.
Further key findings from the report suggest:
• Anti-cancer segment held the largest share in the market in 2019. Approval of the number of drugs and
increasing research in the treatment of cancer are attributing to th